Publications, Pharmaceutical

Improving Intranasal Sprays for Respiratory Viral Infections

Intranasal sprays have considerable potential for the treatment of viral infections such as the SARS-CoV-2 virus which enter via the upper airway.

Download Publication on intranasal sprays for respiratory viral infections
28 Jan 2022

This paper describes work to improve the targeting of drug delivery for such infections by modifying intranasal spray usage protocols. Computational fluid dynamic studies and experimental validation work show that with an improved protocol, involving more shallowed (almost horizontal) angling of the intranasal spray, drug delivery to the nasopharyngeal viral infection ‘hot spot’ can be doubled. The optimal droplet size for drug delivery for such applications is discussed, and the robustness of the developed protocol is highlighted, with respect to the consistency of drug delivery.

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More

This Might Also Be of Interest

5 Jul 2022

Drug, Device, Digital: Reimagined Healthcare

Webinars, Pharmaceutical, Innovation & Insights, Brand Differentiation, Market Insights, Product Solutions

Read More
21 Jun 2022

Nasal Drug Delivery Challenges and Trends Ahead

Publications, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
9 Jun 2022

Aptar Pharma discusses digital therapeutics for chronic conditions

Publications, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
16 May 2022

Healthcare Packaging: The Future of Medical Devices

Publications, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
1 12 13 14 15 16 27

Request Access

Close

Requesting access to Improving Intranasal Sprays for Respiratory Viral Infections.

  • This field is for validation purposes and should be left unchanged.
Back To Top